Table 1 Ongoing clinical trials studying anti-IL-1 strategies (except IL-1β strategies for lung cancer, shown in Table 2), alone or in combination, for cancer treatment
From: Targeting interleukin-1β and inflammation in lung cancer
Therapy | Target | Tumor type | Recruitment status | Study type | ClinicalTrials.gov identifier | Trial name | Start date | Estimated completion date |
|---|---|---|---|---|---|---|---|---|
Anakinra + chemotherapy | IL-1R | Pancreatic adeno-carcinoma | Active, not recruiting | Phase I | NCT02550327 [30] | – | January 16 | August 2023 |
Anakinra + denosumab + everolimus | IL-1R, RANKL, and mTOR | Advanced, metastatic, recurrent or refractory cancer | Active, not recruiting | Phase I | NCT01624766 [31] | – | June 2012 | June 2020 |
CAN04 + chemotherapy | IL-1RAP | NSCLC, pancreatic ductal adenocarcinoma, TNBC, CRC | Recruiting | Phase I/II | NCT03267316 [32] | CANFOUR | December 2017 | June 2021 |
CAN04 + pembrolizumab | IL-1RAP, PD-1 | NSCLC, urothelial carcinoma, malignant melanoma, HNSCC | Recruiting | Phase I | NCT04452214 [33] | – | September 2020 | January 2022 |
Canakinumab | IL-1β | Chronic myelomonocytic leukemia or myelodysplastic syndrome | Recruiting | Phase II | NCT04239157 [34] | – | August 2020 | December 2022 |
Canakinumab + spartalizumab | IL-1β, PD-1 | Melanoma | Recruiting | Phase II | NCT03484923 [35] | PLATforM | September 2018 | April 2022 |
Canakinumab + spartalizumab + LAG525 | IL-1β, PD-1, LAG-3 | TNBC | Recruiting | Phase Ib | NCT03742349 [36] | – | January 2019 | January 2022 |
Canakinumab + spartalizumab + chemotherapy | IL-1β, PD-1 | Pancreatic ductal adenocarcinoma | Recruiting | Phase Ib | NCT04581343 [37] | PanCAN-SR1 | October 2020 | March 2022 |
Canakinumab + spartalizumab | IL-1β, PD-1 | RCC | Recruiting | Phase I | NCT04028245 [38] | SPARC-1 | August 2019 | December 2021 |
Gevokizumab + bevacizumab/ramucirumab/cabozantinib + chemotherapy | IL-1β, VEGF, VEGFR2 | CRC, gastroesophageal cancer, RCC | Recruiting | Phase I | NCT03798626 [39] | – | May 2019 | Jul 2024 |